Want to join the conversation?
Biotechnology company $REGN said that 4Q15 net income rose 72% to $155MM or $1.34 per diluted share vs. $90MM or $0.78 per diluted share in 4Q14. Non-GAAP diluted EPS was $2.83. Total revenues rose by 37% to $1.1Bil, helped by higher net product sales of $750MM in 4Q15. Total revenues also include collaboration revenues of $330MM.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.